denosumab

Details

Instance of

type of chemical entity

Subclass of

chemical compound

active ingredient in

Prolia, Xgeva

defined daily dose

0.33

has characteristic

biopharmaceutical

has use

medication

LiverTox likelihood score

LiverTox toxicity likelihood category E*

medical condition treated

aneurysmal bone cyst, musculoskeletal disorder, osteoarthritis susceptibility 1, postmenopausal osteoporosis, gastroesophageal reflux disease, injury, non-small-cell lung carcinoma, osteoporosis, esophagitis, bone disease, osteomalacia, hyperparathyroidism

physically interacts with

TNF superfamily member 11

pregnancy category

Australian pregnancy category D, US pregnancy category X

subject has role

bone density conservation agents, monoclonal antibody

World Health Organisation international non-proprietary name

denosumab

Connected on Wikidata